Epclusa

Chronic Hepatitis C Treatment

Epclusa is used to treat long-term (chronic) hepatitis C, a viral infection that affects the liver. It is a combination of two antiviral medications, sofosbuvir and velpatasvir, which work together to block the proteins the virus needs to grow and reproduce.

Genotypes and Patient Groups

This medication is approved for use in adults and pediatric patients who are at least 3 years old. It is considered a pangenotypic treatment, meaning it is effective against all six major strains (genotypes 1, 2, 3, 4, 5, and 6) of the hepatitis C virus.

Liver Health Considerations

Epclusa may be prescribed for patients at various stages of liver health:

• Without cirrhosis: For patients who have not developed significant liver scarring.
• Compensated cirrhosis: For patients with liver scarring whose liver is still functioning adequately.
• Decompensated cirrhosis: For patients with advanced liver disease where the liver is failing. In these instances, Epclusa is typically used in combination with another antiviral drug called ribavirin.

Mechanism of Action

Epclusa contains two active ingredients, sofosbuvir and velpatasvir. These are known as direct-acting antivirals (DAAs) because they target the hepatitis C virus (HCV) directly to prevent it from making copies of itself.

Each ingredient targets a specific protein the virus needs to survive and replicate:

• Sofosbuvir: This component is a nucleotide analog polymerase inhibitor. It blocks a protein called NS5B polymerase, which the virus uses to copy its genetic material (RNA). By inhibiting this process, sofosbuvir prevents the virus from reproducing.
• Velpatasvir: This component is an NS5A inhibitor. It targets the NS5A protein, which is necessary for the virus to assemble new viral particles and move them within the cell.

By blocking these two distinct stages of the viral life cycle, the medication lowers the amount of hepatitis C virus in the body to undetectable levels. When the virus can no longer be detected in the blood for 12 weeks or more after finishing treatment, the infection is considered cured.

Common Side Effects

Most people taking Epclusa experience mild side effects. The most frequently reported symptoms include:

• Headache
• Tiredness or fatigue
• Nausea
• Diarrhea
• Difficulty falling asleep or staying asleep

Serious Side Effects

While less common, some side effects can be serious. You should contact a healthcare provider immediately if you experience:

• Allergic reactions: Symptoms may include a severe rash, hives, swelling of the face, lips, tongue, or throat, and difficulty breathing or swallowing.
• Slow heart rate (bradycardia): This risk is specifically for individuals taking the heart medication amiodarone while using Epclusa. Symptoms can include dizziness, fainting, chest pain, or shortness of breath.

Hepatitis B Virus Reactivation

Epclusa has a boxed warning because it can cause the hepatitis B virus (HBV) to become active again in people who currently have or have previously had the infection. HBV reactivation can lead to serious liver problems, including liver failure or death. Healthcare providers typically perform blood tests to check for HBV infection before starting treatment with Epclusa.

Slow Heart Rate (Bradycardia)

Serious slowing of the heart rate, known as bradycardia, can occur when Epclusa is taken with amiodarone, a medication used to treat heart rhythm problems. This risk may be higher in patients also taking beta-blockers or those with underlying heart conditions. Symptoms of a slow heart rate that require medical attention include:

• Fainting or feeling like you might faint
• Dizziness or lightheadedness
• Shortness of breath
• Chest pain
• Weakness or extreme tiredness
• Confusion

Drug Interactions

Epclusa can interact with several other medications, which may reduce its effectiveness or increase the risk of side effects. Significant interactions may occur with:

• Antacids, H2 blockers, and proton pump inhibitors (PPIs)
• Certain seizure medications, such as carbamazepine or phenytoin
• St. John's wort
• Certain cholesterol-lowering statins
• Rifampin

Other Considerations

The safety and effectiveness of Epclusa in patients with severe kidney disease or those undergoing dialysis are still under evaluation. If Epclusa is used in combination with ribavirin, the warnings and precautions associated with ribavirin—including the risk of severe birth defects and fetal death—must also be considered. It is important to discuss all medical conditions and current medications with a healthcare provider before starting treatment.

Pregnancy

There are no adequate studies on the use of Epclusa in pregnant women to determine if there is a risk of birth defects or miscarriage. In animal studies, no harm to the fetus was observed when the components of Epclusa were administered at high doses. However, because human data is limited, healthcare providers typically discuss the potential risks and benefits before starting treatment during pregnancy.

It is important to note that if Epclusa is used in combination with ribavirin, the risks change significantly. Ribavirin is known to cause severe birth defects or the death of an unborn baby. If ribavirin is part of the treatment plan, pregnancy must be avoided by both female patients and the female partners of male patients during treatment and for at least six months after the last dose.

Breastfeeding

It is currently unknown whether the active ingredients in Epclusa, sofosbuvir and velpatasvir, pass into human breast milk or if they affect milk production. The safety of breastfeeding while taking this medication has not been established. Patients should discuss breastfeeding plans with their healthcare provider to weigh the benefits of breastfeeding against any potential risks to the infant.

Available Forms

Epclusa is a fixed-dose combination medication provided in two primary oral formulations:

• Oral Tablets: These are film-coated tablets intended to be swallowed whole.
• Oral Pellets: These pellets are provided in packets. They are designed to be swallowed whole or sprinkled on a small amount of non-acidic soft food for patients who have difficulty swallowing tablets.

FDA Approval and Indications

Epclusa, a combination of sofosbuvir and velpatasvir, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) infection. It is indicated for patients with HCV genotypes 1, 2, 3, 4, 5, or 6. The medication is approved for use in adults and pediatric patients aged 3 years and older.

The treatment regimen depends on the patient's liver function. Epclusa is used alone in patients without cirrhosis or with compensated cirrhosis. For patients with decompensated cirrhosis, it is approved for use in combination with ribavirin.

Boxed Warning

The FDA has issued a boxed warning for Epclusa concerning the risk of hepatitis B virus (HBV) reactivation. In patients coinfected with both HCV and HBV, starting treatment with direct-acting antivirals like Epclusa can cause the hepatitis B virus to become active again. This reactivation can lead to serious liver problems, including liver failure or death. Healthcare providers are required to screen all patients for evidence of current or prior HBV infection before initiating treatment.

Regulatory Status

Epclusa is not a controlled substance. There is currently no Risk Evaluation and Mitigation Strategy (REMS) program required for this medication. It was the first all-oral, pan-genotypic single-tablet regimen approved by the FDA for the treatment of chronic hepatitis C.

Factors Influencing Cost

The total price for a course of Epclusa can vary significantly based on several factors. Because it is a specialty medication, it is usually dispensed through specialty pharmacies rather than standard retail locations. Key factors include:

• Insurance Coverage: Most private insurance plans, Medicare, and Medicaid provide coverage for this medication, though copays and deductibles vary. Some plans may require prior authorization.
• Treatment Duration: A standard treatment course typically lasts 12 weeks, and the total cost is determined by the number of tablets required for the full duration.
• Generic Availability: A generic version containing the same active ingredients (sofosbuvir and velpatasvir) is available and may be a more affordable option depending on your insurance provider's formulary.

Financial Assistance

Patients who are uninsured or have high out-of-pocket costs may be eligible for financial support. The manufacturer often provides patient assistance programs or copay coupons to help reduce expenses for eligible individuals. Additionally, some non-profit organizations offer grants to help cover the cost of chronic hepatitis C medications.